Vertex Enhances its HCV Pipeline by Licensing Alios BioPharma’s Nucleotide Analogues
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 6 (Table of Contents)
Published: 20 Jun-2011
DOI: 10.3833/pdr.v2011.i6.1484 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Within weeks of receiving US FDA approval for its oral hepatitis C virus (HCV) protease inhibitor Incivek™ (telaprevir), Vertex Pharmaceuticals has licensed global rights to two preclinical-stage nucleotide analogues, ALS-2200 and ALS-2158, from Alios BioPharma in a deal potentially worth more than US$1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS